Reports
Sale
North America Hypertrophic Cardiomyopathy Market Size, Share: By Drug Class: Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Others; By Surgeries or other procedures: Septal Myectomy, Septal Ablation, Others; Regional Analysis; Market Dynamics; Supplier Landscape; 2024-2032
North America Hypertrophic Cardiomyopathy Market Size
The North America hypertrophic cardiomyopathy market is expected to grow at a CAGR of 1.21% during the forecast period of 2024-2032, driven by the increased clinical activity and growing demand for minimally invasive procedures in the region.
North America Hypertrophic Cardiomyopathy Market Outlook
- The market demand is driven by the growing preference for minimally invasive procedures such as alcohol ablation due to reduced risk of complications and shorter recovery time.
- The rising integration of artificial intelligence in diagnostic cardiology is one of the major market trends. In August 2023, Viz.ai’s hypertrophic cardiomyopathy artificial intelligence (AI) detection algorithm called the HCM module received De Novo approval from the FDA.
- The market share is influenced by increased clinical activity to expedite the introduction of novel therapies.
North America Hypertrophic Cardiomyopathy Market Analysis
Hypertrophic cardiomyopathy (HCM) is considered the most common genetic cardiovascular disease. It is generally caused by abnormal genes in the heart muscle due to which the heart muscle becomes thick, making it hard for the heart to pump blood properly. The condition affects 700,000 Americans and approximately 15 million people globally . Hypertrophic cardiomyopathy is likely to be underdiagnosed clinically because of few to no symptoms. Substantial investments in the development of advanced HCM therapies and diagnostics by pharmaceutical and biotech firms are contributing to the expansion of the hypertrophic cardiomyopathy market. Further, the rising demand for minimally invasive procedures such as alcohol ablation due to reduced risk of complications and shorter recovery time is expected to drive the North America hypertrophic cardiomyopathy market growth.
One of the major market trends is the rising integration of artificial intelligence in diagnostic cardiology. In August 2023, California-based software company Viz.ai’s hypertrophic cardiomyopathy artificial intelligence (AI) detection algorithm called the HCM module received De Novo approval from the US Food and Drug Administration. The company received financial aid from Bristol Myers Squibb (under a multi-year agreement) for the deployment of the AI-powered algorithm which can be integrated into the Viz.ai Platform. The approval established a new category for cardiovascular machine learning-based notification software. The Viz HCM module can identify suspected HCM cases by automatically reviewing routine electrocardiograms (ECGs) and subsequently notifying the healthcare provider on the Viz mobile application. Such advancements in diagnostic technology are expected to elevate the North America hypertrophic cardiomyopathy market value.
The market share is also influenced by the increasing introduction of innovative therapies. In October 2023, Ohio-based non-profit academic medical centre Cleveland Clinic performed the world’s first-in-human gene therapy (TN-201) developed by Tenaya Therapeutics, Inc. to treat hypertrophic cardiomyopathy as part of a MyPeak-1 Phase 1b clinical trial. This one-time infusion therapy was given to a 27-year-old woman who is reported to be doing well. The trial, which is designed to assess the efficacy, safety, and tolerability of TN-201, is planning to enrol at least six symptomatic adults. The growth in such clinical studies is poised to support the development of novel treatments which will ultimately bolster the market growth.
North America Hypertrophic Cardiomyopathy Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Drug Class | Antiarrhythmic Agents, Anticoagulants, Beta Adrenergic Blocking Agents, Calcium Channel Blockers, Others |
| Surgeries or Other Procedures | Septal Myectomy, Septal Ablation, Implantable Cardioverter-Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT) Device, Ventricular Assist Device (VAD), Pacemaker, Heart Transplant |
| Country | United States, Canada |
Leading Players in the North America Hypertrophic Cardiomyopathy Market
The key features of the market report include clinical trial analysis, patent analysis, grants analysis, funding, and investment analysis along with strategic initiatives, including partnerships, and collaborations analysis by the key players. The major companies in the market are as follows:
Pfizer Inc.
Pfizer Inc., a leading research-based pharmaceutical and biomedical company, is involved in research and development activities to create drugs for hypertrophic cardiomyopathy and other cardiovascular diseases.
Merck & Co., Inc.
Merck & Co., Inc. is committed to developing novel cardiovascular therapies and is engaged in strategic partnerships to expand its market presence.
Bristol Myers Squibb
This American multinational pharmaceutical company is a leading market player. Its cardiac myosin inhibitor drug CAMZYOS (mavacamten) is indicated for obstructive hypertrophic cardiomyopathy (HCM).
Novartis International AG
Global medicine company Novartis International AG’s combination therapy Sacubitril and Valsartan is undergoing a Phase II trial for hypertrophic cardiomyopathy.
Other players in the market include Sanofi, Amgen Inc., AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Surgeries or other procedures |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Hypertrophic Cardiomyopathy Market Overview
3.1 North America Hypertrophic Cardiomyopathy Market Historical Value (2017-2023)
3.2 North America Hypertrophic Cardiomyopathy Market Forecast Value (2024-2032)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 North America Hypertrophic Cardiomyopathy Market Landscape*
5.1 North America Hypertrophic Cardiomyopathy: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 North America Hypertrophic Cardiomyopathy: Product Landscape
5.2.1 Analysis by Drug Class
5.2.2 Analysis by Surgeries or other procedures
6 North America Hypertrophic Cardiomyopathy Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 North America Hypertrophic Cardiomyopathy Market Segmentation (2017-2032)
7.1 North America Hypertrophic Cardiomyopathy Market (2017-2032) by Drug Class
7.1.1 Market Overview
7.1.2 Antiarrhythmic Agents
7.1.3 Anticoagulants
7.1.4 Beta Adrenergic Blocking Agents
7.1.5 Calcium Channel Blockers
7.1.6 Others
7.2 North America Hypertrophic Cardiomyopathy Market (2017-2032) by Surgeries or other procedures
7.2.1 Market Overview
7.2.2 Septal Myectomy
7.2.3 Septal Ablation
7.2.4 Implantable Cardioverter-defibrillator (ICD)
7.2.5 Cardiac Resynchronization Therapy (CRT) Device
7.2.6 Ventricular Assist Device (VAD)
7.2.7 Pacemaker
7.2.8 Heart Transplant
7.3 North America Hypertrophic Cardiomyopathy Market (2017-2032) by Country
7.3.1 Market Overview
7.3.2 United States
7.3.3 Canada
8 United States Hypertrophic Cardiomyopathy Market (2017-2032)
8.1 United States Hypertrophic Cardiomyopathy Market (2017-2032) by Drug Class
8.1.1 Market Overview
8.1.2 Antiarrhythmic Agents
8.1.3 Anticoagulants
8.1.4 Beta Adrenergic Blocking Agents
8.1.5 Calcium Channel Blockers
8.1.6 Others
8.2 United States Hypertrophic Cardiomyopathy Market (2017-2032) by Surgeries or other procedures
8.2.1 Market Overview
8.2.2 Septal myectomy
8.2.3 Septal ablation
8.2.4 Implantable cardioverter-defibrillator (ICD)
8.2.5 Cardiac resynchronization therapy (CRT) device
8.2.6 Ventricular assist device (VAD)
8.2.7 Pacemaker
8.2.8 Heart transplant
9 Canada Hypertrophic Cardiomyopathy Market (2017-2032)
9.1 Canada Hypertrophic Cardiomyopathy Market (2017-2032) by Drug Class
9.1.1 Market Overview
9.1.2 Antiarrhythmic Agents
9.1.3 Anticoagulants
9.1.4 Beta Adrenergic Blocking Agents
9.1.5 Calcium Channel Blockers
9.1.6 Others
9.2 Canada Hypertrophic Cardiomyopathy Market (2017-2032) by Surgeries or other procedures
9.2.1 Market Overview
9.2.2 Septal myectomy
9.2.3 Septal ablation
9.2.4 Implantable cardioverter-defibrillator (ICD)
9.2.5 Cardiac resynchronization therapy (CRT) device
9.2.6 Ventricular assist device (VAD)
9.2.7 Pacemaker
9.2.8 Heart transplant
10 Regulatory Framework
10.1 FDA
11 Clinical Trial Analysis
11.1 Analysis by Trial Registration Year
11.2 Analysis by Trial Status
11.3 Analysis by Trial Phase
11.4 Analysis by Therapeutic Area
11.5 Analysis by Geography
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication Year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by Year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by Departments
13.7 Analysis by Recipient Organization
14 Funding and Investment Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Strategic Initiative
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Supplier Landscape
16.1 Market Share by Top 5 Companies
16.1.1 Market Share Analysis: North America
16.2 Pfizer Inc.
16.2.1 Financial Analysis
16.2.2 Product Portfolio
16.2.3 Demographic Reach and Achievements
16.2.4 Mergers and Acquisitions
16.2.5 Certifications
16.3 Merck & Co., Inc.
16.3.1 Financial Analysis
16.3.2 Product Portfolio
16.3.3 Demographic Reach and Achievements
16.3.4 Mergers and Acquisitions
16.3.5 Certifications
16.4 Bristol Myers Squibb
16.4.1 Financial Analysis
16.4.2 Product Portfolio
16.4.3 Demographic Reach and Achievements
16.4.4 Mergers and Acquisitions
16.4.5 Certifications
16.5 Novartis International AG
16.5.1 Financial Analysis
16.5.2 Product Portfolio
16.5.3 Demographic Reach and Achievements
16.5.4 Mergers and Acquisitions
16.5.5 Certifications
16.6 Sanofi
16.6.1 Financial Analysis
16.6.2 Product Portfolio
16.6.3 Demographic Reach and Achievements
16.6.4 Mergers and Acquisitions
16.6.5 Certifications
16.7 Amgen Inc.
16.7.1 Financial Analysis
16.7.2 Product Portfolio
16.7.3 Demographic Reach and Achievements
16.7.4 Mergers and Acquisitions
16.7.5 Certifications
16.8 AstraZeneca
16.8.1 Financial Analysis
16.8.2 Product Portfolio
16.8.3 Demographic Reach and Achievements
16.8.4 Mergers and Acquisitions
16.8.5 Certifications
16.9 Johnson & Johnson
16.9.1 Financial Analysis
16.9.2 Product Portfolio
16.9.3 Demographic Reach and Achievements
16.9.4 Mergers and Acquisitions
16.9.5 Certifications
16.10 Teva Pharmaceutical Industries Ltd.
16.10.1 Financial Analysis
16.10.2 Product Portfolio
16.10.3 Demographic
16.10.4 Mergers and Acquisitions
16.10.5 Certifications
16.11 AbbVie Inc.
16.11.1 Financial Analysis
16.11.2 Product Portfolio
16.11.3 Demographic Reach and Achievements
16.11.4 Mergers and Acquisitions
16.11.5 Certifications
17 North America Hypertrophic Cardiomyopathy Market – Distribution Model (Additional Insight)
17.1 Overview
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Payment Methods (Additional Insight)
19.1 Government Funded
19.2 Private Insurance
19.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 1.21% during the forecast period of 2024-2032, driven by increased clinical activity in the region.
Advancements in diagnostic technologies and rising healthcare expenditure are fuelling the demand for the market.
One of the significant trends in the market is the growing emphasis on the development of innovative therapies. In October 2023, Cleveland Clinic performed the world’s first-in-human gene therapy (TN-201) developed by Tenaya Therapeutics, Inc. to treat hypertrophic cardiomyopathy as part of a MyPeak-1 Phase 1b clinical trial.
Based on the drug class, the market is segmented into antiarrhythmic agents, anticoagulants, beta-adrenergic blocking agents, and calcium channel blockers, among others.
Surgeries or other procedures available in the market include septal myectomy, septal ablation, implantable cardioverter-defibrillator (ICD), cardiac resynchronization therapy (CRT) device, ventricular assist device (VAD), pacemaker, and heart transplant.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are Pfizer Inc., Merck & Co., Inc., Bristol Myers Squibb, Novartis International AG, Sanofi, Amgen Inc., AstraZeneca, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER